Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer-Reference-Cited by-同舟云学术

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

Published:2022-07-01 Issue:7 Volume:8 Page:1001
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Heudel Pierre¹²³,Frenel Jean-Sébastien³⁴,Dalban Cécile⁵,Bazan Fernando³⁶,Joly Florence³⁷,Arnaud Antoine³⁸,Abdeddaim Cyril³⁹,Chevalier-Place Annick³⁹,Augereau Paule³¹⁰,Pautier Patricia³¹¹,Chakiba Camille³¹²,You Benoit²³¹³¹⁴,Lancry-Lecomte Laurence³¹⁵,Garin Gwenaelle⁵,Marcel Virginie²¹⁶¹⁷,Diaz Jean Jacques²¹⁶¹⁷,Treilleux Isabelle³¹⁸,Pérol David⁵,Fabbro Michel¹⁹,Ray-Coquard Isabelle¹²³

Affiliation:

1. Medical Oncology Department, Centre Léon Bérard, Lyon, France

2. University Claude Bernard Lyon 1, Lyon, France

3. Groupe d’Investigateurs National des Etudes des Cancers Ovariens et du Sein, France

4. Medical Oncology Department Institut Cancérologie de l’Ouest, St Herblain, France

5. Clinical Research Department, Centre Léon Bérard, Lyon, France.

6. Medical Oncology Department, Hôpital Jean Minjoz, Besançon, France

7. Medical Oncology Department, Centre François Baclesse, Caen, France

8. Institut Sainte Catherine, Avignon, France

9. Centre Oscar Lambret, Lille, France

10. Institut Cancérologie Paul Papin, Angers, France

11. Institut Gustave Roussy, Villejuif, France

12. Institut Bergonié, Bordeaux, France

13. Department of Medical Oncology, Centre Hospitalier Lyon Sud, Pierre Bénite, France

14. EMR EA UCBL/HCL 3738 CICLY, Lyon, France

15. Institut Daniel Hollard, Grenoble, France

16. Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France

17. Institut Convergence PLAsCAN, Lyon, France

18. Biopathology Department, Centre Léon Bérard, Lyon, France

19. Medical Oncology Department, Institut de Cancérologie de Montpellier, Montpellier, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2792232/jamaoncology_heudel_2022_oi_220015_1658255469.79883.pdf

Reference46 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.;Ferlay;Int J Cancer,2010

2. Cancer statistics, 2018.;Siegel;CA Cancer J Clin,2018

3. Cancer treatment and survivorship statistics, 2019.;Miller;CA Cancer J Clin,2019

4. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer.;Creasman;Int J Gynaecol Obstet,2006

5. Classification of endometrial carcinoma: more than two types.;Murali;Lancet Oncol,2014

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification;Journal of Clinical Oncology;2024-01-01

2. Le groupe FRANCOGYN : bilan et avenir;Gynécologie Obstétrique Fertilité & Sénologie ;2024-01

3. Advances in the regulatory mechanisms of mTOR in necroptosis;Frontiers in Immunology;2023-12-18

4. Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma;Cancer Biomarkers;2023-12-15

5. Glycolysis-mTORC1 crosstalk drives rapid proliferation in patient-derived endometrial cancer spheroids with ALDH activity;2023-12-05